Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Preclinical studies with Erlotinib (Tarceva).

Robert W Akita1, Mark X Sliwkowski

  • 1Department of Molecular Oncology, Genentech, Inc, South San Francisco, CA, 94080-4990, USA.

Seminars in Oncology
|July 4, 2003
PubMed
Summary

Erlotinib HCl is a targeted therapy that inhibits epidermal growth factor receptor (EGFR) tyrosine kinase. Preclinical studies show its effectiveness against various cancers and potential for combination therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results.

Nature communications·2024
Same author

Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells.

Molecular cancer therapeutics·2018
Same author

Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates.

Cancer research·2017
Same author

High cell-surface density of HER2 deforms cell membranes.

Nature communications·2016
Same author

HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment.

Cancer immunology research·2016
Same author

Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers.

Molecular cancer therapeutics·2015

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Erlotinib HCl (Tarceva) is an oral, selective inhibitor of epidermal growth factor receptor (HER1/EGFR) tyrosine kinase.
  • EGFR signaling is implicated in tumorigenesis, making its inhibition a therapeutic strategy.

Purpose of the Study:

  • To review the preclinical activity of erlotinib.
  • To explore the potential of erlotinib in combination therapies.

Main Methods:

  • Review of in vitro and in vivo preclinical studies.
  • Analysis of combination studies with chemotherapeutic agents, radiotherapy, and targeted agents.

Main Results:

  • Erlotinib demonstrated activity against colorectal, head and neck, non-small cell lung, and pancreatic tumor cells.
  • Combination of erlotinib with other agents showed additive antitumor effects without increased toxicity in preclinical models.
  • Potential activity against HER2-dependent tumors was also suggested.

Conclusions:

  • Preclinical data support the clinical investigation of erlotinib.
  • Further research is needed to fully understand the regulation and influence of erlotinib's antitumor activity.

Related Experiment Videos